WHO’S MORE AT RISK FROM THE C-19 INJECTIONS?

And Why Are Some People Perfectly Okay?

To answer this question, we must first choose an adverse event that is more likely to be reported to the vaccine adverse event reporting system (VAERS), such as death.  We also need to be aware that underreporting is a huge issue, where only a fraction (<1%) of actual adverse events are reported (1).  Steve Kirsch and Dr. Jessica Rose have calculated the underreporting factor to be 41 and 31, respectively (2,3).  This means that you will need to multiple the number of adverse events by the underreporting factor to get a more accurate estimation of the total number of reports.  More serious events are more likely to be reported but there is also an issue with reports being removed, without explanation and not due to duplicate reporting.  I will not get into that can of worms, but I do believe death is a good AE to use for this analysis.

The first step to understand the cause of these deaths is to look at the temporality (kinetics) by days to onset or days post-injection.  Of note is that if these jabs have caused none of the reported deaths you would see a straight line (there would be no correlation or pattern when plotted by days post-injection.)  What stands out to me is that most deaths occur within the first 48 hours after inoculation.  Let’s assume that many of the deaths on day 0 may be from anaphylaxis to the lipid nanoparticle (Pfizer & Moderna) or adenovirus (Janssen) carriers or adjuvants.  Now we can focus on what is causing the deaths during those first 48 hours which are not anaphylaxis related.

But first we need to look at the dose response curves to see if the pattern is temporally consistent when comparing doses.

Yes, the pattern of deaths is consistent between doses.

Now we can deal with the real question.  What is causing these deaths?  There is ample research on the toxicity of the spike protein causing microvascular damage through microthrombi and inflammatory pathways that can lead to severe thrombi, emboli, strokes, and heart attacks.  What’s more is that the spike protein binds to angiotensin converting enzyme 2 (ACE2) receptors and causes downregulation.  This down regulation is responsible for destabilization and destruction of vascular endothelium.  There is also evidence of the spike protein further disrupting the connections between endothelial cells and crossing the blood brain barrier (4-13).

Here’s what we don’t know, or rather what’s been purposely hidden from independent scientists, the pharmacokinetics (how chemicals move through the body) of the LNP and adenovirus carriers, the expression kinetics and distribution of spike producing cells, and the metabolism and degradation of the carriers, free spike, spike exosomes, and spike apoptotic vesicles.  We can estimate these variables from research on similar carriers and we can estimate the expression kinetics of spike protein as being similar to antibody titers, with a lag period where spike is expressed before antibodies are produced and subsequently detected.  Dr. Jessica Rose wrote an excellent article about information that was lacking, literally redacted, and blacked out from the Nonclinical Evaluation Report BNT162b2 [mRNA] COVID-19 vaccine (COMIRNATY™) (14, 15).  Andreas Oehler also wrote an excellent article on the expression kinetics of the spike protein (16).

(This figure is conceptual and an unfinished work in progress.)

Based on the kinetic profile of reported deaths after injection and results from the Brigham Woman’s/Harvard Study (17), and other resources posted below I have made the following assumptions.  The depth of the injection determines the biodistribution of the carrier with deeper intra-muscular (IM) injections more likely to have a systemic distribution and more rapid expression.  Superficial IM injections will produce more localized expression of the spike protein, a longer delay until spike is expressed and a longer duration of expression (19).  It is the deeper injections with early, systemic expression of spike that would best fit the AE observations (20-29).  We do not know if it’s the free spike or the spike produced on endothelial membranes and exosomes that is more dangerous.  I propose 3 hypotheses to explain the temporality of these events, keeping in mind the 48-hour window.

1.      Expressed free spike protein and spike protein embedded on the surface of exosomes triggers immediate clotting and inflammatory damage to the vascular endothelium, in addition to causing the downregulation of ACE2 receptors.

2.      The vascular endothelial cells that express the spike protein are immediately attacked by cross-reactive antibodies, which trigger apoptosis (cell death.)  This would cause the same inflammation, clotting, and vascular damage as in hypothesis 1.  This hypothesis is based on the fact that it takes longer than 48 hours for the expressed spike protein to produce an antibody response.

3.      Both 1 & 2 are occurring.

Now here’s where I want to be clear that these are working hypotheses that I will continue to refine as more evidence becomes available.  I don’t by any means claim to have it all figured out, nor can I be certain without having access to industry studies and redacted information.  But if any of these hypotheses are correct, the following list are those who would have an increased risk of adverse reactions following one of these injections.

·        Those who are recently COVID-19 recovered

·        Those with inflammatory disease (such as diabetes, cardiovascular disease, & obesity)

·        Those with autoimmune conditions

·        Those with senescent or weakened immune systems

·        Those with mitochondrial and thyroid disease (endothelial repair and regeneration is already impaired) (30)

·        Those on certain medications may also have an increased risk, such as those on beta blockers or ACE 2 inhibitors but there are many confounders, and this needs further research

I also want to address the question of why some people do not suffer any adverse effects from these injections.  We are still in a clinical trial and only Comirnaty is FDA approved, which is not available in the United States.  Since all the available products in the US are still under EUA, they can legally contain different formulations and doses in their products, including placebos.  Please don’t take my word for it, check out (https://clinicaltrials.gov/ct2/show/NCT04368728?term=nct04368728&draw=2&rank=1) and type in NCT04368728 to see that we are all lab rats in this huge population level experiment (14, 31).  Further, excellent researchers such as Dr. Jessica Rose, Albert Benavides, and others have found that some lots are associated with a greater number of adverse events, although there are questions on this issue that have not been resolved yet. 

Lastly, we may very well start to see some of the longer-term adverse effects from these experimental products.  Dr. Ryan Cole is finding an explosion of cancers and latent viral infections in his practice.  A radiologist has found a 360% increase in axillary lymphadenopathy after the jab.  There are cases of aggressive cancer progression and rare cancers.  There are cases of reactivated infections of Epstein Bar, shingles, tuberculosis, and herpes.  I don’t know how the very visible deaths of many young athletes can be ignored.  The harm is real and I’m sorry to those who were not given proper informed consent of the risks.  We can’t change the past, but we can use this information to protect the children.  In children these experimental gene therapies, have no benefit and only the potential for harm, and children may be adversely affected for the rest of their lives.  Please get more information and consider the missing safety data before allowing your children to be injected.  God bless!

My sincere apologies if I left out a reference.  I would love to know your thoughts on this.

References:

1.      Lazarus R., et al. (2010). Electronic Support for Public Health–Vaccine Adverse Event Reporting System (ESP:VAERS) Accessed 10/25/2021, https://digital.ahrq.gov/sites/default/files/docs/publication/r18hs017045-lazarus-final-report-2011.pdf

2. Kirsch S., et al. (2021). Estimating the number of COVID vaccine deaths in America. https://docs.google.com/document/d/1stq2nHFjAcMHhxJhWiXa33wl6x0Ga1qdIxodZnFixRw/edit#

3. Rose J. 2021. Critical appraisal of VAERS Pharmacovigilance:  Is the U.S. vaccine adverse events reporting system (VAERS) a functioning pharmacovigilance system? Science, Public Policy, and the Law; Clinical and Translational Research 3:100-129.  Accessed 11/10/2021, https://resistance-mondiale.com/wp-content/uploads/2021/11/adf864_0490c898f7514df4b6fbc5935da07322.pdf

4. Lyons-Weiler J. 2021.  Five Studies on mRNA Vaccine Spike Protein Pathogenicity. Share with Your Doctor.  Ignore the “Fact Checker” Opinion Web Sites.  Here’s a Collection of Resources on Spike Protein Pathogenicity for Your Use.  Add Your Own in the Comments.

5. Kostoff RN, Calina D, Kanduc D, Briggs MB, Vlachoyiannopoulos P, Svistunov AA, Tsatsakis A. 2021. Why are we vaccinating children against COVID-19? Toxicology reports 8:1665-1684.Lai CC, Chen IT, Chao CM, Lee PI, Ko WC, Hsueh PR. 2021. COVID-19 vaccines: concerns beyond protective efficacy and safety. Expert Rev Vaccines 20(8):1013-1025.

6.      Lei Y, Zhang J, Schiavon CR, He M, Chen L, Shen H, Zhang Y, Yin Q, Cho Y, Andrade L et al. . 2021. SARS-CoV-2 Spike Protein Impairs Endothelial Function via Downregulation of ACE 2. Circulation research 128(9):1323-1326.

7.      Meo SA, Bukhari IA, Akram J, Meo AS, Klonoff DC. 2021. COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines. Eur Rev Med Pharmacol Sci 25(3):1663-1669.

8.      Miller ER, Moro PL, Cano M, Shimabukuro TT. 2015. Deaths following vaccination: What does the evidence show? Vaccine 33(29):3288-3292.

9.      Nicolai L, Leunig A, Pekayvaz K, Anjum A, Riedlinger E, Eivers L, Hoffknecht M-L, Rossaro D, Escaig R, Kaiser R et al. . 2021. Thrombocytopenia and splenic platelet directed immune responses after intravenous ChAdOx1 nCov-19 administration. bioRxiv:2021.06.29.450356.

10.   Raghavan S, Kenchappa DB, Leo MD. 2021. SARS-CoV-2 Spike Protein Induces Degradation of Junctional Proteins That Maintain Endothelial Barrier Integrity. Frontiers in Cardiovascular Medicine 8(582).

11.   Wiese O, Zemlin AE, Pillay TS. 2021. Molecules in pathogenesis: angiotensin converting enzyme 2 (ACE2). J Clin Pathol 74(5):285-290.

12.   Xia X. 2021. Detailed Dissection and Critical Evaluation of the Pfizer/BioNTech and Moderna mRNA Vaccines. Vaccines 9(7):734.

13. Kirsch S. 2021.  New VAERS analysis reveals hundreds of serious adverse events that the CDC and FDA never told us about.  They missed hundreds of serious adverse events that are more elevated than myocarditis.  A new VAERS analysis done by Albert Benavides blows the doors off the “safe and effective” narrative.

14. Nonclinical Evaluation Report:  BNT162b2 [mRNA] COVID-19 vaccine (COMIRNATY ™)  2021.  Submission No:  PM-2020-05461-1-2  Sponsor:  Pfizer Australia Pty Ltd. https://www.tga.gov.au/sites/default/files/foi-2389-06.pdf

15. Rose J. 2021.  “The shortcoming of the repeat dose toxicity study design should not preclude approval of the vaccine.” https://jessicar.substack.com/p/the-shortcoming-of-the-repeat-dose

16. Oehler A. 2021.  Does mRNA in Jabs Really Produce S Spike from SARS-CoV02? The evidence points to something else altogether.

17.   Ogata AF, Cheng C-A, Desjardins M, Senussi Y, Sherman AC, Powell M, Novack L, Von S, Li X, Baden LR et al. . 2021. Circulating Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccine Antigen Detected in the Plasma of mRNA-1273 Vaccine Recipients. Clinical Infectious Diseases:ciab465.

18.   Bansal S, Perincheri S, Fleming T, Poulson C, Tiffany B, Bremner RM, Mohanakumar T. 2021. Cutting Edge: Circulating Exosomes with COVID Spike Protein Are Induced by BNT162b2 (Pfizer–BioNTech) Vaccination prior to Development of Antibodies: A Novel Mechanism for Immune Activation by mRNA Vaccines. The Journal of Immunology:ji2100637.

19.   Pardi N, Tuyishime S, Muramatsu H, Kariko K, Mui BL, Tam YK, Madden TD, Hope MJ, Weissman D. 2015. Expression kinetics of nucleoside-modified mRNA delivered in lipid nanoparticles to mice by various routes. Journal of controlled release: official journal of the Controlled Release Society 217:345-351.

20.   Kose N, Fox JM, Sapparapu G, Bombardi R, Tennekoon RN, de Silva AD, Elbashir SM, Theisen MA, Humphris-Narayanan E, Ciaramella G et al.  2019. A lipid-encapsulated mRNA encoding a potently neutralizing human monoclonal antibody protects against chikungunya infection. Sci Immunol 4(35).

21.   Palmer M & Bhakdi S.  2021.  Long-term persistence of the SARS-CoV-2 spike protein:  evidence and implications. https://doctors4covidethics.org/long-term-persistence-of-the-sars-cov-2-spike-protein-evidence-and-implications-2/.

22.   Wolff JA, Malone RW, Williams P, Chong W, Acsadi G, Jani A, Felgner PL. 1990. Direct gene transfer into mouse muscle in vivo. Science 247(4949 Pt 1):1465-8.

23.   Zhang L, Richards A, Barrasa MI, Hughes SH, Young RA, Jaenisch R. 2021. Reverse-transcribed SARS-CoV-2 RNA can integrate into the genome of cultured human cells and can be expressed in patient-derived tissues. Proceedings of the National Academy of Sciences 118(21):e2105968118.

24.   Shepherd E. 2018. Injection technique 1: administering drugs via the intramuscular route. Nursing Times 114(8):23-25.

25.   Polania Gutierrez JJ, Munakomi S. 2021. Intramuscular Injection. StatPearls. Treasure Island (FL): StatPearls Publishing Copyright © 2021, StatPearls Publishing LLC.

26.   Suk JS, Xu Q, Kim N, Hanes J, Ensign LM. 2016. PEGylation as a strategy for improving nanoparticle-based drug and gene delivery. Adv Drug Deliv Rev 99(Pt A):28-51.

27.  https://www.pmda.go.jp/drugs/2021/P20210212001/672212000_30300AMX00231_I100_1.pdf

28.   https://trialsitenews.com/did-pfizer-fail-to-perform-industry-standard-animal-testing-prior-to-initiation-of-mrna-clinical-trials/

29.   https://childrenshealthdefense.org/defender/covid-vaccine-spike-protein-travels-from-injection-site-organ-damage/?utm_source=salsa&eType=EmailBlastContent&eId=736ed55c-1837-43b8-95c6-9ed1d9d01cc8

30. Jiang H, Mei Y-F. 2021. SARS-CoV-2 Spike Impairs DNA Damage Repair and Inhibits V(D)J Recombination In Vitro. Viruses 13(10):2056.

31. NIH Clinical Trials (2021). NCT04368728 https://clinicaltrials.gov/ct2/show/NCT04368728?term=nct04368728&draw=2&rank=1